Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.

CNMPA Approved World's First Inhaled COVID-19 Vaccine Mist

The liquid form of the vaccine is changed into an aerosol using a nebulizer. It can then be inhaled through the mouth using the nebulizer machine. According to CanSino, the vaccine can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath.

Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps

Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.

Chinese Inactivated Vaccines against Omicron Variant Approved for Clinical Trial

Will the approval of the inactivated vaccines against Omicron variants help contain the spike in Covid-19 infections across China?